Table 3.
Patient characteristics for tet2-DMC–low and –high*
| Characteristics | tet2-DMC– low | tet2-DMC– high | P |
|---|---|---|---|
| Total No. | 56 | 130 | |
| Age, mean (range), y | 50 (19–68) | 49 (17–73) | .96 |
| Male sex, No. (%) | 22 (39) | 64 (49) | .26 |
| Bone marrow blasts at diagnosis, mean (range), % | 53 (8–96) | 57 (10–99) | .32 |
| WBC at diagnosis, mean (range), 103/uL | 22 (1–148) | 26 (1–228) | .71 |
| Cytogenetic risk group, No. (%) | .34 | ||
| Favorable | 2 (4) | 1 (1) | |
| Intermediate | 31 (55) | 77 (62) | |
| Poor | 23 (41) | 47 (38) | |
| Antecedent hematologic disorder, No. (%) | 13 (23) | 25 (19) | .56 |
| Complete remission rate, No. (%) | 46 (82) | 95 (73) | .2 |
| Overall survival, median (range), mo | 74+ (0–79+) | 14 (0–82+) | .0004 |
| Mutations, No. (%) | |||
| FLT3-ITD | 9 (17) | 25 (20) | .68 |
| FLT3-TKD | 3 (6) | 10 (8) | .76 |
| RAS | 5 (10) | 17 (15) | .46 |
| NPM1 | 13 (28) | 20 (19) | .21 |
| IDH1 | 2 (4) | 6 (5) | 1 |
| IDH2 | 3 (6) | 10 (8) | .76 |
| IDH1/2 | 5 (9) | 15 (12) | .8 |
| DNMT3A | 7 (13) | 14 (11) | .8 |
* The P values were computed from Fisher’s exact test for two-by-two contingency analyses, Mann-Whitney test to compare continuous variables (age, bone marrow blasts at diagnosis, and WBC at diagnosis), and the log-rank test for survival data. All P values were two-tailed, and the threshold of statistical significance was P < .05. tet2-DMCs = TET2-specific differentially methylated CpGs.